Status:
COMPLETED
A Simple Approach to Prevent Hospitalization for COVID-19 Patients
Lead Sponsor:
Mario Negri Institute for Pharmacological Research
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
The newly recognised disease COVID-19 is caused by the Severe-Acute-Respiratory-Syndrome Coronavirus 2 (SARS-CoV-2), which rapidly spread globally in late 2019, reaching pandemic proportions. The clin...
Eligibility Criteria
Inclusion
- Male and female adult (≥18 years old)
- Subjects with early mild symptoms of COVID-19, who start the treatment without waiting results of a nasopharyngeal swab, if any
- Informed consent
Exclusion
- Subjects of the two cohorts who require immediate hospital admission because of severe COVID-19 symptoms at onset according to family doctor's assessment
Key Trial Info
Start Date :
July 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 21 2021
Estimated Enrollment :
216 Patients enrolled
Trial Details
Trial ID
NCT04854824
Start Date
July 1 2021
End Date
December 21 2021
Last Update
March 21 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
ASL Teramo
Teramo, TE, Italy, 64100
2
ATS Insubria
Varese, VA, Italy, 21100